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Introduction
Renal angiomyolipomas (AMLs) are one of the most common benign kidney
tumors diagnosed. They account for about 1% of surgically resected renal
lesions and affect women more than men [1]. Majority of AMLs are found
incidentally, but patients may present with relatively nonspecific symptoms such
as flank pain, hematuria, and abdominal pain. Grossly, these tumors are highly
vascular and grow exophytically, making retroperitoneal bleeding the most
dangerous complication in affected patients [2,3]. Histologically, these tumors
consist of dysmorphic blood vessels, spindled smooth muscle cells, and
adipocytes [4]. AMLs are traditionally grouped into two categories: classic and
syndromic. Classic AMLs account for 80% of cases, and syndromic AMLs
account for 20%. Associated syndromes include tuberous sclerosis and
lymphangioleiomyomatosis [5].
Epithelioid AMLs (eAMLs) are a third category that can arise from any types of
AMLs. They are distinguished from other AMLs due to the presence of
epithelioid cells [4]. This rare variant has been classified by the World Health
Organization as a potentially malignant mesenchymal neoplasm that
metastasizes in one-third of cases [6]. However, conflicting reports have
brought in to question their true malignant potential [7]. Due to eAMLs overall
rarity, few studies have characterized this entity. In this study, we further define
eAML by describing its genomic alterations and malignant potential by
comparing it to a cohort of AML patients at a large-volume cancer center.
 Prospectively maintained kidney cancer database queried for all patients with
eAML and AML who underwent nephrectomy between 1994 and 2008 at the
Memorial Sloan Kettering Cancer Center.
 Patients separated into two histologic groups: eAML and AML.
 Clinicopathologic features and genomic alterations analyzed and compared.
 Descriptive statistics performed using Mann-Whitney U test and Chi-squared
test. All statistical analyses performed using R 3.5.2 with significance set at
<0.05.
 Overall survival (OS) and recurrence-free survival (RFS) data analyzed using
Kaplan-Meier method with significance determined by log-rank tests.
 Genomic data gathered for 6 eAML and 10 AML patients.
Method
 Out of 103 patients, 44 had eAML and 59 had AML.
 Women in their fifth and sixth decade were more commonly diagnosed than
men, Table 1.
 Patients with eAML had larger tumors (p<0.001) and underwent radical
nephrectomy more often (p=0.014).
 Twelve (27.3%) eAML patients metastasized, while no metastases were
observed in AML patients.
 Median RFS for eAML patients was 131 months, and median RFS was not
reached in AML patients (p<0.0001), Figure 1.
 The most frequently mutated gene across both groups expectedly was TSC2,
a mutation commonly found in AMLs.
 The mutational burden in eAMLs was heterogeneous compared to AMLs, with
more mutations observed within TP53 (43%), RB1 (14%), APC (14%), TERT
(14%), ATRX (14%), TSC1 (14%), PIK3CA (14%), GNA11 (14%), and FGFR3
(14%), Figure 2.
Discussion
 Patients with eAML were observed to have larger tumors and metastasized at
a higher rate than patients with AML.
 A greater frequency of eAML patients underwent radical nephrectomy.
 The mutational burden across eAML was notable for a more heterogeneity,
with largest mutations in TSC2 and TP53 genes.
 Further investigation into the impact of mutational burden on metastatic
potential is warranted.
Conclusion
Results Figure 1: Overall and Recurrence-Free Survival in eAML and AML Patients
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Figure 2: Percent Comparison of Mutational Landscape 
Between eAML and AML
Epithelioid AML AML p
Patients (n) 44 59
Age (Median [IQR]) 58.00 [43.57, 64.29] 53.00 [48.00, 63.50] 0.963
Sex (%)
Women
Men
30 (68.2)
14 (31.8)
49 (83.1)
10 (16.9)
0.126
BMI (Median [IQR]) 26.30 [23.90, 28.90] 27.50 [23.90, 31.65] 0.331
Symptoms (%)
Incidental
Symptomatic 
23 (54.8)
19 (45. 2)
33 (62.3)
20 (37.7)
0.597
Type of Nephrectomy (%)
Partial
Radical
23 (54.8)
19 (45.2)
47 (79.7)
12 (20.3)
0.014
Laterality (%)
Left
Right
21 (47.7)
23 (52.3)
32 (55.2)
26 (44.8)
0.586
Single Lesion (%) 42 (95.5) 50 (84.7) 0.156
Tumor Size (Median [IQR]) 4.00 [2.50, 8.80] 2.00 [1.45, 2.80] <0.001
Positive Margins (%) 3 (8.6) 5 (8.5) 1
Metastasized (%) 12 (27.3) 0 (0.0) <0.001
Table 1:
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 Median RFS was worse in 
eAML than in AML patients.
 Patients with eAML had 
larger tumors and more 
underwent radical 
nephrectomy.
 Patients with eAML 
metastasized more.
 Patients with eAML had more 
heterogeneous mutations.
 TSC2 was the most 
frequently mutated gene in 
both groups.
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